Selecta Biosciences, Inc.
NASDAQ:SELB
Overview | Financials
Company Name | Selecta Biosciences, Inc. |
Symbol | SELB |
Currency | USD |
Price | 0.881 |
Market Cap | 135,200,754 |
Dividend Yield | 0% |
52-week-range | 0.785 - 1.99 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Carsten Brunn Ph.D. |
Website | https://selectabio.com |
An error occurred while fetching data.
About Selecta Biosciences, Inc.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD